Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Adds $200M to Share Repurchase Program

NEW YORK (GenomeWeb) – Myriad Genetics announced today that its board has approved an additional $200 million for its share buyback program.

Since the inception of the repurchase program in 2010, the company said it has bought back approximately $1.1 billion in stock as of the end of its fiscal third quarter at an average share price of $26.16. When reporting its Q3 earnings a month ago, the firm said it bought back approximately 1.2 million shares, or $45 million worth, of common stock during the quarter, and ended Q3 with around $47 million in its current share repurchase authorization.

"Our priorities for capital deployment remain the same. First, internal research and development, followed by acquisitions, and lastly, share repurchases," said CFO Bryan Riggsbee in a statement. "We will continue to opportunistically repurchase shares at valuation thresholds that we believe do not reflect the inherent value of the company and as we look to deploy our capital most effectively to maximize shareholder returns over the long-term."

Myriad's shares were up more than 2 percent to $35.22 in morning trading on the Nasdaq.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.